Clinical research

Comparison of eligible non-enrolled patients and the randomised TWENTE trial population treated with Resolute and XIENCE V drug-eluting stents

EuroIntervention 2012;8:664-671. DOI: 10.4244/EIJV8I6A104

Hanim Sen
Hanim Sen1, MD; Kenneth Tandjung1, MD; Mounir W.Z. Basalus1, MD; Marije M. Löwik1, PhD; Gert K. van Houwelingen1, MD; Martin G. Stoel1, MD; Hans W. Louwerenburg1, MD; Frits H.A.F. de Man1, MD, PhD; Gerard C.M. Linssen3, MD, PhD; Rogier Nijhuis4, MD, PhD; Mark B. Nienhuis5, MD, PhD; Patrick M.J. Verhorst1, MD, PhD; Job van der Palen6,7, PhD; Clemens von Birgelen1,2*, MD, PhD
1. Department of Cardiology, Thoraxcentrum Twente, Medisch Spectrum Twente, Enschede, The Netherlands; 2. MIRA, Institute for Biomedical Technology and Technical Medicine, University of Twente, Enschede, The Netherlands; 3. Department

Aims: The TWENTE trial recently enrolled more than 80% of all eligible patients, who were randomised to zotarolimus-eluting Resolute or

Sign in to read and download the full article

Forgot your password?

No account yet?
Sign up for free!

Create my pcr account

Join us for free and access thousands of articles from EuroIntervention, as well as presentations, videos, cases from

clinical researchpercutaneous coronary interventioncoronary artery diseaserandomised controlled trialtwente trial
Read next article
Triple antithrombotic therapy following an acute coronary syndrome: prevalence, outcomes and prognostic utility of the HAS-BLED score

Latest news